NGR 6172 Pharm EX1 Questions With Correct Answers

Aspirin- MOA - Answer Binds irreversibly to cyclooxyrgenase-1 and 2 (COX 1 and 2) Decrease prostaglandin and thromboxane A2 production Plavix (clopidogrel) -MOA - Answer Produg- irreversibly inhibits P2Y12 ADP-mediated platelet activation and aggregation Boxed warning of Plavix - Answer conversion to active metabolite require (CYP 450 2C19) Poor metabolizers - higher CV events Plavix- avoid to take with what - Answer 2c19 inhibitors (omeprazole, esomeprazole) increased bleed post CABG how long for antiplatelet therapy? - Answer 1 year Post bare metal stent placement: how long for antiplatelet therapy? - Answer 1 month or less Drug - eluting stent placement: how long for anti platelet therapy? - Answer 6 months or less P2Y12 inhibitors MOA - Answer Binds the adenosine diphosphate (ADP) P2Y12 receptor on the platelet surface Prevents activation of the GPIIb/IIIa receptor complex Reduces platelet aggregation Brilinta - Answer Not program; P2Y12 INHIBITOR DRUG reversibly binds P2Y12 inhibitor drugs - Answer Plavix (clopidogrel) Brinlinta (ticagrelor) Effient (prasugrel) Kengreal (cangrelor) Glycoprotein 2b/3a receptor antagonist - Answer Block platelet glycoprotein IIb/IIIa receptor (binding site for fibrinogen, von Willebrand factor, other ligands) blocks platelet aggregation ******* prevents further thrombosis Reversible blockades of Glycoprotein 3b/2a receptor antagonists - Answer Integrilin (eptifibatide) Aggrastat (tirofiban) irreversible blockades of Glycoprotein 3b/2a receptor antagonists - Answer ReoPro (abciximab) what do Fibrinolytics do? - Answer Breakdown clot by binding to fibrin in a clot